Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Beam Therapeutics

    Client Virtual Booth

    BEAM THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Beam Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    26 Landsdowne Street 2nd Floor Cambridge, MA 02139
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://beamtx.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/beamtx
    Twitter
    Twitter
    https://twitter.com/beamtherapeuti1?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-clearance-clinical-trial

    PRESS RELEASE
    26 Mar 2024
    Share Share
    Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
    Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-participate-upcoming-march-2024-investor

    PRESS RELEASE
    28 Feb 2024
    Share Share
    Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
    Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-fourth-quarter-and-year-end-2023

    PRESS RELEASE
    27 Feb 2024
    Share Share
    Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-participate-guggenheim-healthcare-talks-6th

    PRESS RELEASE
    05 Feb 2024
    Share Share
    Beam Therapeutics Appoints Christi Shaw to its Board of Directors
    Beam Therapeutics Appoints Christi Shaw to its Board of Directors

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-appoints-biotech-executive-christi-shaw-its

    PRESS RELEASE
    14 Dec 2023
    Share Share
    Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
    Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-participate-2023-jefferies-london-healthcare

    PRESS RELEASE
    08 Nov 2023
    Share Share
    Beam Therapeutics Reports Third Quarter 2023 Financial Results
    Beam Therapeutics Reports Third Quarter 2023 Financial Results

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-reports-pipeline-and-business-updates-and

    PRESS RELEASE
    08 Nov 2023
    Share Share
    Beam offloads Verve rights to Lilly for up to $600M
    Beam offloads Verve rights to Lilly for up to $600M

    https://www.fiercebiotech.com/biotech/beam-offloads-verve-rights-lilly-600m-and-more-deals-are-works

    Max Bayer FIERCE BIOTECH
    31 Oct 2023
    Share Share
    Beam Therapeutics Presents Data Highlighting Utility and Durability of BEAM-301
    Beam Therapeutics Presents Data Highlighting Utility and Durability of BEAM-301

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-preclinical-data-highlighting-0

    PRESS RELEASE
    25 Oct 2023
    Share Share
    Beam Therapeutics Announces Portfolio Prioritization & Strategic Restructuring
    Beam Therapeutics Announces Portfolio Prioritization & Strategic Restructuring

    https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-portfolio-prioritization-and

    PRESS RELEASE
    19 Oct 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search